Novavax bets fears over mRNA expertise will give its Covid jab an edge
Novavax mentioned its protein-based Covid-19 vaccine can be a robust competitor to the BioNTech / Pfizer and Moderna jabs regardless of its late arrival due to public issues over the protection of its rivals’ messenger RNA expertise.
However the US biotech, which started delivery its vaccine to Europe and Asia in January following months of lengthy delays due to regulatory challenges, has referred to as on Washington to do extra to advertise its vaccine, which has nonetheless not been approved by US regulators.
“I might love to listen to extra public assist from the US authorities and I have no idea whether or not they’ve been too concerned in among the different vaccines or they’ve been too busy,” mentioned Stan Erck, chief government of Novavax, including US authorization for its jab may occur “inside weeks”.
The World Well being Group, the UK, EU and Australia are amongst virtually a dozen international locations and organizations to approve Novavax’s two-dose vaccine, which is the primary product launched by the corporate in its 34-year historical past. Novavax plans to ship 2bn doses in 2022, which analysts’ forecast may generate $ 5bn in revenues – a transformational occasion for a biotech that has been a perennial loss maker.
However the firm has struggled to offer information to US regulators that exhibit it might probably manufacture jabs in a constant method. This has triggered delays to the roll out of its two-dose vaccine, which scientific trials present has 90 p.c efficacy in opposition to symptomatic Covid-19. It adopted the award of US authorities contracts value $ 1.8bn to Novavax to develop its vaccine and provide 100m doses.
Stan Erck at a gathering with the Coronavirus Activity Drive and pharmaceutical executives on the White Home in March 2020
Erck informed the Monetary Instances these issues had been resolved and Novavax would quickly start delivery doses to the US from its manufacturing companion, the Serum Institute of India. He mentioned there may be nonetheless loads of demand for the corporate’s jab in high-income international locations although vaccination charges are excessive, citing contracts for 69m doses agreed with the EU in December.
“This places a giant stamp of approval on our vaccine in high-income international locations,” Erck mentioned, including the corporate is in talks with US authorities about what number of doses it might ship and when.
Novavax mentioned its jab may assist sort out vaccine hesitancy in developed nations as a result of it’s made utilizing a standard vaccine manufacturing methodology somewhat than mRNA expertise, a brand new platform that has develop into a goal for misinformation by antivax campaigners. The corporate has additionally prompt its protein-based expertise may present extra sturdy safety in opposition to Covid with out a danger of myocarditis – a price coronary heart situation that has been linked to mRNA jabs.
Greg Glenn, Novavax’s president of R&D, mentioned the mRNA vaccines have some “security” and points when it comes to antagonistic unwanted effects, which might make Novavax a very enticing choice when Covid-19 turns into endemic.
“Myocarditis. I imply it actually occurs, ”he informed the FT.
“The evaluation has been made in the present day that the chance and the result of that, which is you understand not rare, is balanced with the chance of getting Covid. . . However the presentation is fairly unhealthy. Individuals who have myocarditis- they’ve extreme chest ache, it’s tough for the household and 96 per cent get hospitalized. ”
Nevertheless, Novavax has not finished a head-to-head research pitting its jab in opposition to both the BioNTech / Pfizer or Moderna vaccines to offer correct information evaluating security and antagonistic reactions.
David Dowdy, an epidemiologist at Johns Hopkins Faculty of Drugs, mentioned the primary message is that present information confirmed that the entire extensively used vaccines are exceptionally protected.
“With merchandise which might be this protected, it’s extra vital to get individuals vaccinated than to haggle over small variations in security,” he mentioned.
Dowdy mentioned the Novavax vaccine might be a game-changer in some lower-income nations because it doesn’t want very chilly storage – an element that has hampered distribution of mRNA vaccines in Africa.
Novavax mentioned it intends to win a race with its mRNA opponents to realize approval for a mixed flu and Covid-19 shot, with a goal date of 2024, and ship on a pipeline of different respiratory medicine.